GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (AMEX:MTNB) » Definitions » Volatility

Matinas BioPharma Holdings (Matinas BioPharma Holdings) Volatility : 111.73% (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Matinas BioPharma Holdings Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-22), Matinas BioPharma Holdings's Volatility is 111.73%.


Competitive Comparison of Matinas BioPharma Holdings's Volatility

For the Biotechnology subindustry, Matinas BioPharma Holdings's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Volatility distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Volatility falls into.



Matinas BioPharma Holdings  (AMEX:MTNB) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Matinas BioPharma Holdings  (AMEX:MTNB) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Matinas BioPharma Holdings Volatility Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Executives
Liu Hui officer: Chief Technology Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Thomas Hoover officer: Chief Business Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad director C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii officer: Chief Medical Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits officer: Chief Development Officer C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler director VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino officer: Chief Scientific Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921